Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Saved in:
| Title: | Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. |
|---|---|
| Authors: | Nguyen TTA; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA., Postlewait LM; Division of Surgical Oncology, Department of Surgery, Emory University, Atlanta, GA, USA., Zhang C; Pediatric Biostatistics Core, Department of Pediatrics, Emory University, Atlanta, GA, USA., Meisel JL; Department of Hematology and Oncology, Emory University, Atlanta, GA, USA., O'Regan R; Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA., Badve S; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA., Kalinsky K; Department of Hematology and Oncology, Emory University, Atlanta, GA, USA., Li X; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA. xli40@emory.edu. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Apr; Vol. 192 (3), pp. 509-516. Date of Electronic Publication: 2022 Jan 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-022-06530-6 |
